CHRS - CIK 0001512762
Coherus BioSciences, Inc. trades as CHRS. In its fiscal 2025 annual report the company posted revenue of $42.17M, up 59.8% from the prior year and net income of $168.02M. This page tracks Coherus BioSciences, Inc. through 898 SEC filings, with financial statements and metrics updated as new reports are filed.
Over the last 9 fiscal years Coherus BioSciences, Inc.'s revenue declined from $190.11M to $42.17M, a compound annual decline rate of 15.4%. Net profit margin expanded from -67.0% to 398.4% over the same period - every figure below comes from the company's audited annual filings.
| Filing | Type | Filed |
|---|---|---|
| Proxy materials | DEFA14A | 2026-05-28 |
| SCHEDULE 13G/A | - | 2026-05-15 |
| SCHEDULE 13G/A | - | 2026-05-11 |
| Quarterly report | 10-Q | 2026-05-11 |
| Major company event | 8-K | 2026-05-11 |
| Proxy materials | DEFA14A | 2026-05-05 |
| SCHEDULE 13G/A | - | 2026-04-29 |
| SCHEDULE 13G/A | - | 2026-04-27 |
The largest companies sharing Coherus BioSciences, Inc.'s SEC industry classification (biological products, (no diagnostic substances)).
Coherus BioSciences, Inc. reported revenue of $42.17M for fiscal year 2025, an increase of 59.8% year over year.
Yes. Coherus BioSciences, Inc. reported net income of $168.02M in its latest fiscal year.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.